Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology.
State-of-the-art R&D facilities, with a chemical library of over 240,000 molecules, 60% of which are proprietary.
Inventiva in Numbers
Partnerships (Abbvie and Boehringer Ingelheim)
Innovative Clinical Programmes
People in our Scientific Team
A Library of
Welcome to Inventiva Pharma
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.
Leveraging these assets and expertise, we are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
February 13, 2019
Publication of revenues and cash position
as of December 31, 2018
February 27, 2019
2018 annual financial results
Last update: Sep 13, 2019 at 17:24 CET
Previous close: €2.02
Day High: €2.04
Day Low: €2.01
Non-Alcoholic Steatohepatitis (NASH)
Non-alcoholic steatohepatitis is a severe liver disease which affects 6-8% of adults in western industrialised nations and is on the rise around the globe.
Inventiva is developing lanifibranor for the treatment of NASH to address all the key features of NASH: inflammation, steatosis, ballooning, and importantly fibrosis.
We are currently investigating lanifibranor for the treatment of NASH in NATIVE, a Phase 2b clinical trial, with results expected in the first half of 2020.
MPS is a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells.
Inventiva is developing odiparcil, an orally-available small molecule designed to modify how GAGs are synthesized.
We are currently investigating odiparcil in iMProveS, a Phase 2a clinical trial, with results expected in the second half of 2019.